Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2022 07:30 ET | Source: Aravive, Inc.

Aravive Announces Approximately $41.5 Million Private Placement Financing

HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced...
October 10, 2022 16:05 ET | Source: Aravive, Inc.

Aravive Receives Third Development Milestone from 3D Medicines

HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
September 26, 2022 08:00 ET | Source: Aravive, Inc.

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
September 06, 2022 16:05 ET | Source: Aravive, Inc.

Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
August 11, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data.Presented Updated...
July 05, 2022 09:07 ET | Source: Aravive, Inc.

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
June 03, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Appoints Rudy Howard as Chief Financial Officer

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
May 26, 2022 17:11 ET | Source: Aravive, Inc.

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a...
May 17, 2022 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in H.C. Wainwright Global Investment Conference

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail...
May 12, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCCPresented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right